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Direct oral anticoagulants 
or warfarin for A fib?
A recent study evaluated the effectiveness of 3 direct 
oral anticoagulants and warfarin in patients with atrial 
fibrillation. So which agents came out on top? 
PRACTICE CHANGER
Use direct oral anticoagulants instead of war-
farin in patients with atrial fibrillation be-
cause they are just as effective at preventing 
ischemic stroke and systemic emboli as war-
farin, and because apixaban and dabigatran 
have lower bleeding rates. 
STRENGTH OF RECOMMENDATION 
B: Based on a single, prospective, cohort 
study.
Larsen TB, Skjøth F, Nielsen PB, et al. Comparative effectiveness and 
safety of non-vitamin K antagonist oral anticoagulants and warfarin in 
patients with atrial fibrillation: propensity weighted nationwide cohort 
study. BMJ. 2016;353:i3189.1
ILLUSTRATIVE CASE
A 66-year-old man with a history of hyper-
tension and diabetes mellitus type 2 is hos-
pitalized for palpitations and dizziness, and 
is given a diagnosis of atrial fibrillation (AF). 
His heart rate is successfully controlled with 
a beta-blocker. His CHA2DS2-VASc score is 
3, meaning he is a candidate for anticoagula-
tion. Which agent should you start?
Thromboembolism in patients with AF results in stroke and death and can be decreased with appropriate use 
of antithrombotic therapy. Evidence-based 
guidelines recommend patients with AF at 
intermediate or high risk of stroke (CHADS2 
score ≥2 or prior history of cardioembolic 
stroke or transient ischemic attack) receive 
antithrombotic therapy with oral anticoagu-
lation, rather than receive no  therapy or ther-
apy with antiplatelets.2,3
The American College of Chest Physi-
cians also recommends the use of the direct 
oral anticoagulant (DOAC) dabigatran over 
warfarin for those patients with nonvalvular 
AF with an estimated glomerular filtration rate 
(eGFR) ≥15 mL/min/1.73 m2.3  
A meta-analysis of large randomized 
controlled trials (RCTs) of individual DOACs 
(dabigatran [a direct thrombin inhibitor], riva-
roxaban, apixaban, and edoxaban [factor Xa 
inhibitors]) revealed similar or lower rates of 
ischemic stroke and major bleeding (except 
gastrointestinal bleeds; relative risk=1.25; 
95% CI, 1.01 to 1.55) when compared with 
warfarin (at an international normalized ra-
tio [INR] goal of 2-3).4 In addition, 3 separate 
meta-analyses that pooled results from large 
RCTs involving dabigatran, apixaban, and 
rivaroxaban also concluded that these medi-
cations result in a significant reduction in 
embolic stroke and reduced the risk of major 
bleeds and hemorrhagic stroke when com-
pared with warfarin.5-7 
However, we know less about the com-
parative effectiveness and safety of the 
DOACs when they are used in clinical prac-
tice, and it is not clear which, if any of these 
agents, are superior to others. Moreover, only 
about half of the patients in the United States 
with AF who are eligible to take DOACs are 
currently managed with them.8 
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STUDY SUMMARY 
One DOAC is better than warfarin at 
one thing; 2 others are better at another
This large cohort study examined the effec-
tiveness of 3 DOACs compared with warfa-
rin in 61,678 patients with AF by combining 
data from 3 Danish national databases. The 
patients had newly diagnosed AF (without 
valvular disease or venous thromboembo-
lism) and were prescribed standard doses 
of DOACs (dabigatran 150 bid [N=12,701], 
rivaroxaban 20 mg/d [N=7192], apixaban 
5 mg bid [N=6349]) or dose-adjusted war-
farin to an INR goal of 2 to 3 (N=35,436). 
Patients were followed for an average of 
1.9 years.  
❚ Ischemic stroke, systemic emboli. 
In the first year of observation, there were 
1702 ischemic strokes or systemic emboli. 
The incidence of ischemic stroke or systemic 
embolism was either the same or better 
for each of the 3 DOAC treatments than 
for warfarin (DOACs, 2.9-3.9 events per 
100 person-years; warfarin, 3.3 events per 
100 person-years; no P value provided). 
Ischemic stroke or systemic emboli events 
occurred less frequently in the rivaroxaban 
group compared with warfarin at one year 
(hazard ratio [HR]=0.83; 95% confidence 
interval [CI], 0.69-0.99) and after 2.5 years 
(HR=0.80; 95% CI, 0.69-0.94). The rates of 
ischemic stroke and systemic emboli for 
both apixaban and dabigatran were not sig-
nificantly different than that for warfarin at 
one year and 2.5 years.  
❚ Bleeding events (defined as intracra-
nial, major gastrointestinal, and traumatic 
intracranial) were lower in the apixaban 
group (HR=0.63; 95% CI, 0.53-0.76) and 
dabigatran group (HR=0.61; 95% CI, 0.51-
0.74) than in the warfarin group at one 
year. Significant reductions remained af-
ter 2.5 years. There was no difference in 
bleeding events between rivaroxaban and 
warfarin. 
❚ Risk of death. Compared with warfa-
rin, the risk of death after one year of treat-
ment was lower in the apixaban (HR=0.65; 
95% CI, 0.56-0.75) and dabigatran (HR=0.63; 
95% CI, 0.48-0.82) groups, and there was 
no significant difference in the rivaroxaban 
group (HR=0.92; 95% CI, 0.82-1.03).
WHAT’S NEW
No agent “has it all,” 
but DOACs have advantages
This comparative effectiveness and safety 
analysis reveals that all of the DOACs are at 
least as effective as warfarin in preventing 
ischemic stroke and systemic emboli, and 
that rivaroxaban may be more effective, and 
that apixaban and dabigatran have a lower 
risk of bleeding than warfarin.
CAVEATS
This non-randomized cohort trial  
lacked INR data 
This study was a non-randomized cohort 
trial. And, while propensity weighting helps, 
the researchers were unable to completely 
control for underlying risk factors or un-
known confounders.  
INR data for patients on warfarin was not 
provided, so it is not clear how often patients 
were out of therapeutic range, which could 
affect the stroke and bleeding results in the 
warfarin group. This, however, is seen with 
routine use of warfarin. We feel that this study 
reflects the challenge of maintaining patients 
in warfarin’s narrow therapeutic range.  
CHALLENGES TO IMPLEMENTATION
It comes down to cost
Cost could be a barrier, as health insurance 
coverage for DOACs varies. Patients with high-
deductible health insurance plans, or who find 
themselves in the Medicare “donut hole,” may 
be at a particular disadvantage.                 JFP
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